Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MOREReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREBuilding on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MOREYour new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREEmpowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSThe Department of Health & Human Services (HHS) and Centers for Medicare & Medicaid Services proposed new rules in October 2019 that have the potential to impact the Life Sciences industry and the relationships companies have with Healthcare Professionals (HCPs) and Healthcare Organizations (HCOs).
Among other things, the proposed changes would modify the personal services safe harbor provisions of the Anti-Kickback Statute (AKS) as well as create some new safe harbor protections. According to the HHS, these modifications would roll back barriers that currently inhibit improvements in patient care coordination and allow pharmaceutical and medical device manufacturers to participate more fully in the patient continuum of care, while still providing robust safeguards to defend against the potential for fraud and abuse.
With the proposed rule modification to the personal services safe harbor provision, pharmaceutical and medical device manufacturers no longer must predetermine a level of aggregate compensation in advance of initiating a relationship. They also would no longer be compelled to predetermine exact schedules, length and charge for such intervals — current stipulations that can effectively function as barriers inhibiting more flexible models of HCP education and patient care delivery. For example, agreements between manufacturers and HCPs for as-needed consulting or speaking services would be more likely to meet the revised personal services safe harbor, provided that compensation is fair market value and the other requirements are met. This simplification would free manufacturers from a layer of burdensome and cost-inefficient administrative requirements.
HHS has established a public comment period to gather feedback on its proposed changes to the AKS and Stark Law; this comment period ended December 31, 2019. These are important developments for pharmaceutical and medical device manufacturers, and this evolution of regulatory protocol in the age of value-based healthcare should be watched closely by all industry stakeholders.
IQVIA assists companies in meeting the safe harbors of the AKS including the calculation of FMV. We welcome the opportunity to further discuss these changes. For more information, please email commercialcompliance@iqvia.com or visit our webpage.